Genscript Biotech Corporation
1548
Rank in Stocks
#2092
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Share Price
$4.39
Market Cap
$9.87B
Change (1 day)
2.69%
Change (1 year)
110.37%
Country
HK
Trade Genscript Biotech Corporation (1548)
Category
Healthcare
Number of shares outstanding for Genscript Biotech Corporation (1548)
Number of shares outstanding as of June 2026: 2.19B
According to Genscript Biotech Corporation latest financial reports and stock price the company's current number of shares outstanding is 2.19B. At the end of December 2023 the company had 2.11B shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Genscript Biotech Corporation (1548) from 2013 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 2.19B | 0.32% |
| 2024 | 2.18B | 3.27% |
| 2023 | 2.11B | 0.61% |
| 2022 | 2.10B | 3.28% |
| 2021 | 2.03B | 6.80% |
| 2020 | 1.90B | 2.58% |
| 2019 | 1.85B | 3.39% |
| 2018 | 1.79B | 4.55% |
| 2017 | 1.71B | 2.82% |
| 2016 | 1.67B | 39.80% |
| 2015 | 1.19B | -1.53% |
| 2014 | 1.21B | -24.31% |
| 2013 | 1.60B | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -88.38% |
US
|
|
| 396.00M | -81.88% |
US
|
|
| 478.91M | -78.09% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -97.15% |
NL
|
